Close Menu

ALK Biomarkers

News and reporting on ALK biomarkers.

The expanded indication makes it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.

A big bump in service revenues made up for a decline in product revenues. The company also trimmed its operating expenses and narrowed its net loss. 

The assay can be used to identify patients suitable for treatment with ALK-targeted therapeutics such as Pfizer's Xalkori.

Using mass spec and small hairpin RNA, they built a map of ALK signaling and identified proteins that could sensitize tumor cells to inhibitor treatment.

Data from the meeting suggest that lung cancer patients with ALK-positive tumors may soon have two first-line options and more choices when their disease progresses.

Repeat molecular analysis of a patient's cancer helped clinicians guide targeted therapies as drug resistance emerged and ebbed.

Genentech's Alecensa and AstraZeneca's Tegrisso are the latest precision lung cancer drugs, and Xalkori might soon be an option for a new molecular subpopulation.

The preliminary results showed that 76 percent of study subjects under 40 had druggable mutations.

In developing the recommendations, the expert panel attempted to keep up with the fast-moving advances in oncology.

The non-small cell lung cancer drug now has two FDA-approved companion tests, Abbott's FISH test and Ventana's IHC test, for identifying patients most likely to benefit from treatment.

Pages

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.